ArticleTechniques in coloproctology2025
Perioperative efficacy and safety of short-course radiotherapy combined with immunochemotherapy in proficient mismatch repair rectal cancer.
Article in Techniques in coloproctology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe purpose of this study was to compare the perioperative efficacy and safety of neoadjuvant chemoradiotherapy (NCRT) alone versus short-course radiotherapy combined with immunochemotherapy (SCRT + ICT) in patients with proficient mismatch repair (pMMR) rectal cancer.
methodsThis study was designed as a single-center, retrospective, case-matched analysis conducted at a tertiary referral center. The patient cohort consisted of individuals diagnosed with pMMR rectal cancer between 2022 and 2024. The main outcome measures evaluated were pathological complete response (pCR) rate, anus preservation rate, neoadjuvant therapy-related adverse events, and surgery-related complications.
resultsIn the final analysis, 46 pairs of patients were included. The SCRT + ICT group had a significantly higher pathological complete response (pCR) rate (47.8% versus 10.9%, P < 0.001) and anus preservation rate (84.8% versus 37.0%, P < 0.001), but also a higher temporary stoma rate (76.1% versus 21.7%, P < 0.001). Both groups achieved a 100% R0 resection rate. Regarding safety, the combined therapy group had lower intraoperative blood loss (20 ml versus 50 ml, P < 0.001) and shorter postoperative hospital stay (6 days versus 8 days, P < 0.001). Adverse events and postoperative complications were similar in both groups. Additionally, logistic regression analysis showed that SCRT + ICT is a protective factor for achieving postoperative pCR, while intraoperative blood loss ≥ 50 ml and elevated pretreatment carcinoembryonic antigen (CEA) levels are risk factors for postoperative pCR.
conclusionsShort-course radiotherapy combined with immunochemotherapy is safe and effective for patients with pMMR rectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.